Semin Neurol 2023; 43(01): 035-047
DOI: 10.1055/s-0043-1763510
Review Article

Drug-Induced Movement Disorders

Sanjay Pandey
1   Department of Neurology, Amrita Hospital, Faridabad, Delhi National Capital Region, India
,
Yuvadee Pitakpatapee
2   Division of Neurology, Department of Medicine, Faculty of Medicine, Mahidol University, Siriraj Hospital, Thailand
,
Weerawat Saengphatrachai
2   Division of Neurology, Department of Medicine, Faculty of Medicine, Mahidol University, Siriraj Hospital, Thailand
,
Anjali Chouksey
3   Department of Neurology, Shri Narayani Hospital and Research Centre, Vellore, Tamil Nadu, India
,
Madhavi Tripathi
4   Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India
,
Prachaya Srivanitchapoom
2   Division of Neurology, Department of Medicine, Faculty of Medicine, Mahidol University, Siriraj Hospital, Thailand
› Author Affiliations
Funding We declare that there are no additional disclosures to report.

Abstract

Drug-induced movement disorders (DIMDs) are most commonly associated with typical and atypical antipsychotics. However, other drugs such as antidepressants, antihistamines, antiepileptics, antiarrhythmics, and gastrointestinal drugs can also cause abnormal involuntary movements. Different types of movement disorders can also occur because of adverse drug reactions. Therefore, the important key to diagnosing DIMDs is a causal relationship between potential offending drugs and the occurrence of abnormal movements. The pathophysiology of DIMDs is not clearly understood; however, many cases of DIMDs are thought to exert adverse mechanisms of action in the basal ganglia. The treatment of some DIMDs is quite challenging, and removing the offending drugs may not be possible in some conditions such as withdrawing antipsychotics in the patient with partially or uncontrollable neuropsychiatric conditions. Future research is needed to understand the mechanism of DIMDs and the development of drugs with better side-effect profiles. This article reviews the phenomenology, diagnostic criteria, pathophysiology, and management of DIMDs.

Ethical Compliance Statement

Approval from the institutional review board or ethics committee was not required for this work. Informed patient consent was not necessary for this work. We confirm that we have read the journal's position on issues involved in ethical publication and affirm that this work is consistent with those guidelines.


Author Contributions

1. Research project: A, conception; B, organization; C, execution.


2. Statistical analysis: A, design; B, execution; C, review and critique.


3. Manuscript: A, writing of the first draft; B, review and critique.


S.P.: 1A, 1B, 1C, 2A, 2B, 2C, 3A, 3B.


Y.P.: 1A, 1B, 1C, 2A, 2B, 2C, 3A, 3B.


W.S.: 1A, 1B, 1C, 2A, 2B, 2C, 3A, 3B.


A.C.: 1A, 1B, 1C, 2A, 2B, 2C, 3A, 3B.


M.T.: 1A, 1B, 1C, 2A, 2B, 2C, 3A, 3B.


P.S.: 1A, 1B, 1C, 2A, 2B, 2C, 3A, 3B.




Publication History

Article published online:
24 February 2023

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 
  • References

  • 1 Claxton KL, Chen JJ, Swope DM. Drug-induced movement disorders. J Pharm Pract 2007; 20 (06) 415-429
  • 2 Ali T, Sisay M, Tariku M, Mekuria AN, Desalew A. Antipsychotic-induced extrapyramidal side effects: a systematic review and meta-analysis of observational studies. PLoS One 2021; 16 (09) e0257129
  • 3 Roiter B, Pigato G, Antonini A. Prevalence of extrapyramidal symptoms in in-patients with severe mental illnesses: focus on parkinsonism. Front Neurol 2020; 11: 593143
  • 4 Caroff SN, Campbell EC. Drug-induced extrapyramidal syndromes: implications for contemporary practice. Psychiatr Clin North Am 2016; 39 (03) 391-411
  • 5 Factor SA, Burkhard PR, Caroff S. et al. Recent developments in drug-induced movement disorders: a mixed picture. Lancet Neurol 2019; 18 (09) 880-890
  • 6 Barnhill JW. DSM-5® Clinical Cases [Internet]. American Psychiatric Publishing; 2013 [cited December 3, 2019]. Accessed January 30, 2023 at: http://psychiatryonline.org/doi/book/10.1176/appi.books.9781585624836
  • 7 Burkhard PR. Acute and subacute drug-induced movement disorders. Parkinsonism Relat Disord 2014; 20 (Suppl. 01) S108-S112
  • 8 Yoon JH, Lee PH, Yong SW, Park HY, Lim TS, Choi JY. Movement disorders at a university hospital emergency room: an analysis of clinical pattern and etiology. J Neurol 2008; 255 (05) 745-749
  • 9 Dallocchio C, Matinella A, Arbasino C. et al. Movement disorders in emergency settings: a prospective study. Neurol Sci 2019; 40 (01) 133-138
  • 10 Tousi B. Movement disorder emergencies in the elderly: recognizing and treating an often-iatrogenic problem. Cleve Clin J Med 2008; 75 (06) 449-457
  • 11 Dale RC, Singh H, Troedson C, Pillai S, Gaikiwari S, Kozlowska K. A prospective study of acute movement disorders in children. Dev Med Child Neurol 2010; 52 (08) 739-748
  • 12 Tardive dyskinesia: summary of a Task Force Report of the American Psychiatric Association. By the task force on late neurological effects of antipsychotic drugs. Am J Psychiatry 1980; 137 (10) 1163-1172
  • 13 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, DSM-IV TR. Washington, DC: 2000: 803-805
  • 14 American Psychiatric Association. Diagnostic and Statistical Manual. 5th ed.. Washington, DC: American Psychiatric Association; 2013
  • 15 Lee Y, Yeh WC, Chong MY, Lin PY, Chang YY. Venlafaxine and tardive blepharospasm: a case report. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31 (05) 1139-1140
  • 16 Birthi P, Walters C, Karandikar N. A rare case of tardive dyskinesia and akathisia induced by citalopram. PM R 2010; 2 (10) 973-975
  • 17 Albayrak Y, Ekinci O. Duloxetine-associated tardive dyskinesia resolved with fluvoxamine: a case report. J Clin Psychopharmacol 2012; 32 (05) 723-724
  • 18 Fann WE, Sullivan JL, Richman BW. Dyskinesias associated with tricyclic antidepressants. Br J Psychiatry 1976; 128: 490-493
  • 19 Dekret JJ, Maany I, Ramsey TA, Mendels J. A case of oral dyskinesia associated with imipramine treatment. Am J Psychiatry 1977; 134 (11) 1297-1298
  • 20 Wain OJJ. Tardive dyskinesia. In: Roos RP. ed. Neurology. San Diego: MedLink Corporation; Available at: wwwmedlinkcom, last updated February 27, 2017
  • 21 D'Abreu A, Akbar U, Friedman JH. Tardive dyskinesia: epidemiology. J Neurol Sci 2018; 389: 17-20
  • 22 Chouksey A, Pandey S. Clinical spectrum of drug-induced movement disorders: a study of 97 patients. Tremor Other Hyperkinet Mov (N Y) 2020; 10: 48
  • 23 Bhidayasiri R, Boonyawairoj S. Spectrum of tardive syndromes: clinical recognition and management. Postgrad Med J 2011; 87 (1024): 132-141
  • 24 Aquino CC, Lang AE. Tardive dyskinesia syndromes: current concepts. Parkinsonism Relat Disord 2014; 20 (Suppl. 01) S113-S117
  • 25 Sigwald J, Bouttier D, Raymondeaud C, Piot C. 4 Cases of facio-bucco-linguo-masticatory dyskinesis of prolonged development following treatment with neuroleptics. [in French]. Rev Neurol (Paris) 1959; 100: 751-755
  • 26 Faurbye A, Rasch PJ, Petersen PB, Brandborg G, Pakkenberg H. Neurological symptoms in pharmacotherapy of psychoses. Acta Psychiatr Scand 1964; 40 (01) 10-27
  • 27 Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov (N Y) 2013; 3: e1-e11
  • 28 Choudhury S, Chatterjee K, Singh R. et al. Levosulpiride-induced movement disorders. J Pharmacol Pharmacother 2017; 8 (04) 177-181
  • 29 Hawthorne JM, Caley CF. Extrapyramidal reactions associated with serotonergic antidepressants. Ann Pharmacother 2015; 49 (10) 1136-1152
  • 30 Wubeshet YS, Mohammed OS, Desse TA. Prevalence and management practice of first generation antipsychotics induced side effects among schizophrenic patients at Amanuel Mental Specialized Hospital, central Ethiopia: cross-sectional study. BMC Psychiatry 2019; 19 (01) 32
  • 31 Chawla S, Kumar S. Adverse drug reactions and their impact on quality of life in patients on antipsychotic therapy at a tertiary care center in Delhi. Indian J Psychol Med 2017; 39 (03) 293-298
  • 32 The use of the WHO–UMC system for standardised case causality assessment [cited 2022 9 July]. Accessed January 30, 2023 at: https://cdn.who.int/media/docs/default-source/medicines/pharmacovigilance/whocausality-assessment.pdf
  • 33 Naranjo CA, Busto U, Sellers EM. et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30 (02) 239-245
  • 34 Shukla AK, Jhaj R, Misra S, Ahmed SN, Nanda M, Chaudhary D. Agreement between WHO-UMC causality scale and the Naranjo algorithm for causality assessment of adverse drug reactions. J Family Med Prim Care 2021; 10 (09) 3303-3308
  • 35 Belhekar MN, Taur SR, Munshi RP. A study of agreement between the Naranjo algorithm and WHO-UMC criteria for causality assessment of adverse drug reactions. Indian J Pharmacol 2014; 46 (01) 117-120
  • 36 Friedman JH. The Naranjo scale and tardive syndromes, a historical perspective. Clin Neuropharmacol 2019; 42 (05) 188
  • 37 Seger D, Barker K, McNaughton C. Misuse of the Naranjo adverse drug reaction probability scale in toxicology. Clin Toxicol (Phila) 2013; 51 (06) 461-466
  • 38 Miller LG, Jankovic J. Neurologic approach to drug-induced movement disorders: a study of 125 patients. South Med J 1990; 83 (05) 525-532
  • 39 Baizabal-Carvallo JF, Morgan JC. Drug-induced tremor, clinical features, diagnostic approach and management. J Neurol Sci 2022; 435: 120192
  • 40 Hauser RA, Meyer JM, Factor SA. et al. Differentiating tardive dyskinesia: a video-based review of antipsychotic-induced movement disorders in clinical practice. CNS Spectr 2022; 27 (02) 208-217
  • 41 Jiménez-Jiménez FJ, García-Ruiz PJ, Molina JA. Drug-induced movement disorders. Drug Saf 1997; 16 (03) 180-204
  • 42 van Strien AM, Keijsers CJ, Derijks HJ, van Marum RJ. Rating scales to measure side effects of antipsychotic medication: a systematic review. J Psychopharmacol 2015; 29 (08) 857-866
  • 43 Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987; 334: 1-100
  • 44 Day JC, Wood G, Dewey M, Bentall RP. A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients. Br J Psychiatry 1995; 166 (05) 650-653
  • 45 Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212: 11-19
  • 46 Janno S, Holi MM, Tuisku K, Wahlbeck K. Validity of Simpson-Angus Scale (SAS) in a naturalistic schizophrenia population. BMC Neurol 2005; 5 (01) 5
  • 47 Knol W, Keijsers CJ, Jansen PA. et al. Validity and reliability of the Simpson-Angus Scale (SAS) in drug induced parkinsonism in the elderly. Int J Geriatr Psychiatry 2009; 24 (02) 183-189
  • 48 Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154: 672-676
  • 49 Barnes TR. The Barnes Akathisia rating scale–revisited. J Psychopharmacol 2003; 17 (04) 365-370
  • 50 Janno S, Holi MM, Tuisku K, Wahlbeck K. Actometry and Barnes akathisia rating scale in neuroleptic-induced akathisia. Eur Neuropsychopharmacol 2005; 15 (01) 39-41
  • 51 Munetz MR, Benjamin S. How to examine patients using the Abnormal Involuntary Movement Scale. Hosp Community Psychiatry 1988; 39 (11) 1172-1177
  • 52 Tonelli H, Tonelli D, Poiani GR, Vital MA, Andreatini R. Reliability and clinical utility of a Portuguese version of the Abnormal Involuntary Movements Scale (AIMS) for tardive dyskinesia in Brazilian patients. Braz J Med Biol Res 2003; 36 (04) 511-514
  • 53 Gerlach J, Korsgaard S, Clemmesen P. et al. The St. Hans Rating Scale for extrapyramidal syndromes: reliability and validity. Acta Psychiatr Scand 1993; 87 (04) 244-252
  • 54 Kim JH, Jung HY, Kang UG. et al. Metric characteristics of the drug-induced extrapyramidal symptoms scale (DIEPSS): a practical combined rating scale for drug-induced movement disorders. Mov Disord 2002; 17 (06) 1354-1359
  • 55 Schneider SA, Udani V, Sankhla CS, Bhatia KP. Recurrent acute dystonic reaction and oculogyric crisis despite withdrawal of dopamine receptor blocking drugs. Mov Disord 2009; 24 (08) 1226-1229
  • 56 Iselin-Chaves IA, Grötzsch H, Besson M, Burkhard PR, Savoldelli GL. Naloxone-responsive acute dystonia and parkinsonism following general anaesthesia. Anaesthesia 2009; 64 (12) 1359-1362
  • 57 Jitprapaikulsan J, Srivanitchapoom P. Acute dystonic reaction following general anesthetic agent use. Tremor Other Hyperkinet Mov (N Y) 2017; 7: 514
  • 58 Pileggi DJ, Cook AM. Neuroleptic malignant syndrome. Ann Pharmacother 2016; 50 (11) 973-981
  • 59 Nisijima K, Shioda K, Iwamura T. Neuroleptic malignant syndrome and serotonin syndrome. Prog Brain Res 2007; 162: 81-104
  • 60 Margetić B, Aukst-Margetić B. Neuroleptic malignant syndrome and its controversies. Pharmacoepidemiol Drug Saf 2010; 19 (05) 429-435
  • 61 Tormoehlen LM, Rusyniak DE. Neuroleptic malignant syndrome and serotonin syndrome. Handb Clin Neurol 2018; 157: 663-675
  • 62 Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med 2005; 352 (11) 1112-1120
  • 63 Gil-Navarro S, Grandas F. Dyskinesia-hyperpyrexia syndrome: another Parkinson's disease emergency. Mov Disord 2010; 25 (15) 2691-2692
  • 64 Calabresi P, Di Filippo M, Ghiglieri V, Tambasco N, Picconi B. Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap. Lancet Neurol 2010; 9 (11) 1106-1117
  • 65 Bologna M, Truong D, Jankovic J. The etiopathogenetic and pathophysiological spectrum of parkinsonism. J Neurol Sci 2022; 433: 120012
  • 66 Martí-Massó JF, Poza JJ. Cinnarizine-induced parkinsonism: ten years later. Mov Disord 1998; 13 (03) 453-456
  • 67 Chung SJ, Yoo HS, Moon H. et al. Early-onset drug-induced parkinsonism after exposure to offenders implies nigrostriatal dopaminergic dysfunction. J Neurol Neurosurg Psychiatry 2018; 89 (02) 169-174
  • 68 Wilbur R, Kulik FA, Kulik AV. Noradrenergic effects in tardive dyskinesia, akathisia and pseudoparkinsonism via the limbic system and basal ganglia. Prog Neuropsychopharmacol Biol Psychiatry 1988; 12 (06) 849-864
  • 69 Naguy A. Clonidine use in psychiatry: panacea or panache. Pharmacology 2016; 98 (1-2): 87-92
  • 70 Mulroy E, Balint B, Bhatia KP. Tardive syndromes. Pract Neurol 2020; 20 (05) 368-376
  • 71 Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: Pathophysiology and mechanisms of induction. Can J Psychiatry 2005; 50 (09) 541-547
  • 72 Booij J, Speelman JD, Horstink MW, Wolters EC. The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med 2001; 28 (03) 266-272
  • 73 Tripathi M, Kumar A, Bal C. Neuroimaging in Parkinsonian disorders. Neurol India 2018; 66 (Supplement): S68-S78
  • 74 Tolosa E, Coelho M, Gallardo M. DAT imaging in drug-induced and psychogenic parkinsonism. Mov Disord 2003; 18 (Suppl. 07) S28-S33
  • 75 Lorberboym M, Treves TA, Melamed E, Lampl Y, Hellmann M, Djaldetti R. [123I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson's disease. Mov Disord 2006; 21 (04) 510-514
  • 76 Tinazzi M, Ottaviani S, Isaias IU. et al. [123I]FP-CIT SPET imaging in drug-induced Parkinsonism. Mov Disord 2008; 23 (13) 1825-1829
  • 77 Vlaar AM, van Kroonenburgh MJ, Kessels AG, Weber WE. Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes. BMC Neurol 2007; 7: 27
  • 78 Biju G, de la Fuente-Fernández R. Dopaminergic function and progression of Parkinson's disease: PET findings. Parkinsonism Relat Disord 2009; 15 (Suppl. 04) S38-S40
  • 79 Diaz-Corrales FJ, Sanz-Viedma S, Garcia-Solis D, Escobar-Delgado T, Mir P. Clinical features and 123I-FP-CIT SPECT imaging in drug-induced parkinsonism and Parkinson's disease. Eur J Nucl Med Mol Imaging 2010; 37 (03) 556-564
  • 80 Burn DJ, Brooks DJ. Nigral dysfunction in drug-induced parkinsonism: an 18F-dopa PET study. Neurology 1993; 43 (3, Pt 1): 552-556
  • 81 Hong JY, Sunwoo MK, Oh JS, Kim JS, Sohn YH, Lee PH. Persistent drug-induced parkinsonism in patients with normal dopamine transporter imaging. PLoS One 2016; 11 (06) e0157410
  • 82 Sagar S, Shankar K, Raj A. et al. Evaluation of 99mTc-TRODAT SPECT in the first year of onset of Parkinsonism. Indian J Nucl Med 2019; 34 (5, Suppl 1): 66
  • 83 Seibyl JP, Marek K, Sheff K. et al. Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurement of dopamine transporters in Parkinson's patients. J Nucl Med 1997; 38 (09) 1453-1459
  • 84 Vlaar AM, de Nijs T, Kessels AG. et al. Diagnostic value of 123I-ioflupane and 123I-iodobenzamide SPECT scans in 248 patients with parkinsonian syndromes. Eur Neurol 2008; 59 (05) 258-266
  • 85 Olivares Romero J, Arjona Padillo A. Diagnostic accuracy of 123 I-FP-CIT SPECT in diagnosing drug-induced parkinsonism: a prospective study. Neurologia 2013; 28 (05) 276-282
  • 86 Rajan S, Kaas B, Moukheiber E. Movement disorders emergencies. Semin Neurol 2019; 39 (01) 125-136
  • 87 Trollor JN, Sachdev PS. Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases. Aust N Z J Psychiatry 1999; 33 (05) 650-659
  • 88 Strawn JR, Keck Jr PE, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry 2007; 164 (06) 870-876
  • 89 Berman BD. Neuroleptic malignant syndrome: a review for neurohospitalists. Neurohospitalist 2011; 1 (01) 41-47
  • 90 Robottom BJ, Weiner WJ, Factor SA. Movement disorders emergencies. Part 1: Hypokinetic disorders. Arch Neurol 2011; 68 (05) 567-572
  • 91 Steckelberg RC, Tsiang D, Pettijohn K, Mendelsohn A, Hoftman N. Acute vocal fold dystonic reaction to propofol: a case report. Am J Otolaryngol 2015; 36 (02) 303-305
  • 92 Pitakpatapee Y, Srikajon J, Sangpeamsook T, Srivanitchapoom P. Rhabdomyolysis associated with severe levodopa-induced dyskinesia in Parkinson's disease: a report of two cases and literature review. Tremor Other Hyperkinet Mov (N Y) 2021; 11: 39
  • 93 Pasricha PJ, Pehlivanov N, Sugumar A, Jankovic J. Drug insight: from disturbed motility to disordered movement – a review of the clinical benefits and medicolegal risks of metoclopramide. Nat Clin Pract Gastroenterol Hepatol 2006; 3 (03) 138-148
  • 94 Zareifopoulos N, Katsaraki M, Stratos P. et al. Pathophysiology and management of Akathisia 70 years after the introduction of the chlorpromazine, the first antipsychotic. Eur Rev Med Pharmacol Sci 2021; 25 (14) 4746-4756
  • 95 Factor SA. Management of tardive syndromes: medications and surgical treatments. Neurotherapeutics 2020; 17 (04) 1694-1712
  • 96 Touma KTB, Scarff JR. Valbenazine and deutetrabenazine for tardive dyskinesia. Innov Clin Neurosci 2018; 15 (5-6): 13-16
  • 97 LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2012. Dantrolene. [Updated January 30, 2017]. Accessed January 30, 2023 at: https://www.ncbi.nlm.nih.gov/books/NBK548144/